Management ChangeJun 29, 2026, 05:21 PM
Cadrenal Therapeutics Appoints John Sharp as Interim CFO
AI Summary
Cadrenal Therapeutics, Inc. announced the appointment of John P. Sharp as Interim Chief Financial Officer, effective June 25, 2026, replacing Quang X. Pham. Mr. Sharp's services will be provided via Lohman & Associates at a rate of $455 per hour for up to 24 hours weekly. Additionally, Steven Zelenkofske resigned from the Board of Directors, effective June 30, 2026, leading to a re-alignment of Board classes and the re-appointment of Dr. Glynn Wilson as a Class III director and to several committees.
Key Highlights
- John P. Sharp appointed Interim Chief Financial Officer, effective June 25, 2026.
- Quang X. Pham ceased to serve as the Company's Interim Chief Financial Officer.
- Mr. Sharp's services will be provided through Lohman & Associates at $455/hour for up to 24 hours per week.
- Steven Zelenkofske resigned from the Board of Directors, effective June 30, 2026.
- Dr. Glynn Wilson re-appointed as a Class III director, effective June 29, 2026.
- Dr. Wilson re-appointed to the Audit, Nominating and Corporate Governance, and Compensation Committees.
- Dr. Wilson's annual compensation for serving on the Board is $35,000 for fiscal year 2026.
Price Impact
More from CVKD